Anasuya Gunturi - Concepedia

Author

Anasuya Gunturi

Dana-Farber Cancer Institute

Also Known As

A Gunturi, A. Gunturi, Anasuya Gunturi, Anna Higham, Misbah U. Qadir

Publications

967

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Massachusetts General Hospital The University of Texas Southwestern Medical Center University of Pittsburgh

About

Anasuya Gunturi is an author at Dana-Farber Cancer Institute specializing in oncology, radiation oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	33
2	Medicine	1	1	33
3	Immunology	1	1	33
4	Clinical Trials	1	1	33
5	Immunotherapy	1	1	33

Anasuya Gunturi

Publications

534

Citations

H-Index

Page 1

	Year	Citations
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors A. B. Ackerman, Oliver Klein, David F. McDermott, Cancer	2014	223
Cutting Edge: Expression of Functional CD94/NKG2A Inhibitory Receptors on Fetal NK1.1+Ly-49− Cells: A Possible Mechanism of Tolerance During NK Cell Development Pallavur V. Sivakumar, Anasuya Gunturi, Margarita Salcedo, The Journal of Immunology	1999	81
Preferential Survival of CD8 T and NK Cells Expressing High Levels of CD94 Anasuya Gunturi, Rance E. Berg, James Forman The Journal of Immunology	2003	77
The role of TCR stimulation and TGF‐β in controlling the expression of CD94/NKG2A receptors on CD8 T cells Anasuya Gunturi, Rance E. Berg, Emily Crossley, European Journal of Immunology	2005	43
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt, Journal for ImmunoTherapy of Cancer	2016	43
Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. A. B. Ackerman, David F. McDermott, Donald P. Lawrence, Journal of Clinical Oncology ImmunologyImmunoeditingMalignant MelanomaDermatologyImmunotherapy	2012	33
Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma David J. Panka, Elizabeth I. Buchbinder, Anita Giobbie‐Hurder, Molecular Cancer Therapeutics	2014	22
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ Ann H. Partridge, Terry Hyslop, Shoshana M. Rosenberg, JAMA Oncology	2024	12

Page 1